Guardant Health Partners with Abu Dhabi for Innovative Colorectal Cancer Screening Program
- Guardant Health partners with Abu Dhabi to launch a non-invasive colorectal cancer screening using the Shield™ test.
- The program aims to improve early detection, addressing late-stage diagnoses of colorectal cancer in the region.
- Guardant Health's commitment to cancer care includes innovative technology and AI analytics for better health outcomes.
Guardant Health Partners with Abu Dhabi to Enhance Colorectal Cancer Screening
Guardant Health, Inc., a leader in precision oncology, forges a significant partnership with the Abu Dhabi Public Health Center (ADPHC) to introduce a groundbreaking non-invasive blood-based colorectal cancer screening program. Utilizing Guardant's Shield™ test, this initiative addresses alarming statistics surrounding colorectal cancer in Abu Dhabi, where it ranks as the third most prevalent cancer. With a staggering 63% of colorectal cancer cases diagnosed at late stages, the program is a strategic move to improve early detection and treatment outcomes in the region.
The Shield test will be integrated into ADPHC's IFHAS comprehensive health screening program, making it accessible at key healthcare facilities operated by Ambulatory Healthcare Services and M42 across Abu Dhabi, Al Ain, and the Al Dhafra region. This initiative aims to tackle the persistent issue of low adherence to cancer screening protocols, which hampers early detection efforts. By enhancing access and streamlining the screening experience, Guardant Health and ADPHC hope to significantly increase participation rates for colorectal cancer screening.
AmirAli Talasaz, co-CEO of Guardant Health, underscores that early detection is linked to improved survival rates, emphasizing the community-focused nature of this program. In its first year, the initiative targets around 10,000 individuals, aiming to foster a more positive and engaging screening experience. Founded in 2012, Guardant Health is committed to transforming cancer care through innovative blood and tissue tests, real-world data, and AI analytics, all geared towards improving health outcomes from early detection to informed treatment selection.
In addition to this important collaboration, Guardant Health continues to enhance its offerings in the oncology space. The company's commitment to advancing cancer care through technology is evident in its integration of AI analytics and real-world data, which support clinicians in making more informed decisions throughout the entire cancer care continuum.
As Guardant Health prepares for future initiatives, it encourages stakeholders to stay informed through its website and social media channels, ensuring that the broader community remains engaged in the fight against cancer.